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MEFVAbstract Background: Henoch–Schӧnlein purpura (HSP) was reported to occur in a number of
patients with Familial Mediterranean Fever (FMF). Furthermore, about 25% of HSP patients have
MEFV gene polymorphisms and that alterations in the MEFV gene are important susceptibility
factors for HSP development, and can affect the clinical presentation of the disease.
Aim of the work: This study was carried out to investigate the prevalence of MEFV gene poly-
morphisms as indicators for subclinical FMF, in Egyptian children with HSP and to study their
relation to the clinical characteristics and laboratory findings.
Patients and methods: The present study included 40 HSP patients and 30 age and sex-matched
healthy children as control. TwelveMEFV genemutations were studied by polymerase chain reaction.
Results: The age of patients at disease onset ranged from 2 to 15 years and mean age at presenta-
tion was 7.5 ± 3.25 years. The male: female ratio was 1:1.3. Positive MEFV gene polymorphism was
found in 70% of patients versus 36.7% of control (p< 0.005). Arthritis, abdominal pain, GIT bleed-
ing, hypertension, anemia, proteinuria, positive occult blood in stools, recurrent HSP and positive
family history were found to bemore frequent presentations accompanying patients with positive gene
polymorphisms. Relation of the MEFV gene polymorphisms with the clinical laboratory findings
indicates that these mutations constitute a significant risk factor for HSP.
Conclusion: Henoch–Schӧnlein purpura has a wide spectrum of presentations and MEFV gene
polymorphism is relevant to its development in Egyptian children. Genetic testing for MEFV gene
is an advisable investigation in cases of HSP.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Henoch–Scho¨nlein purpura (HSP) is a small-vessel vasculitis
that predominantly affects children, but is also seen in adults.
It is a subset of necrotizing vasculitis, characterized by fibri-
noid destruction of blood vessels and leukocytoclasis [1]. Fac-
tors triggering HSP include infections, drugs, food, insect
bites, vaccination and even exposure to cold. The pathogenesis
of HSP is related to aberrant deposition of IgA-containing
immune complexes [2], which typically affects skin, gut,
joints and glomeruli [3].Clinical manifestations of the disease
primarily include palpable purpura, arthralgia or arthritis,
abdominal pain, gastrointestinal (GI) bleeding and nephritis
[1].
Familial Mediterranean Fever (FMF) is an autosomal
recessive disorder characterized by recurrent attacks of fever
and painful serositis [4], and is caused by mutations in the
Mediterranean fever (MEFV) gene [5]. FMF may coexist with
various systemic inflammatory diseases including vasculitides.
This association does not merely show a coincidentally
increased frequency of vasculitic disorders in FMF; rather, it
seems that FMF patients might be at increased risk of develop-
ing vasculitis. Making it an essential feature. Among the vas-
culitic disorders reported to be associated with FMF, HSP
comes first with an obvious clinical significance of FMF-
related MEFV gene polymorphism [6].
Increased frequency of HSP in patients with FMF has been
reported [7]. Approximately 5% of children with FMF have
been postulated to have HSP [8]. HSP is usually a benign
and self-limiting disease with an excellent prognosis that has
been reported to be the presenting feature of FMF [9].
Garshoni-Baruch et al. [10] found that 27% of patients suf-
fering from HSP have MEFV mutations. Furthermore, it has
also been suggested that alterations in the MEFV gene are
important susceptibility factors for the development of HSP
and can also affect the clinical presentation of the disease
[11]. Genetic study allows the confirmation of the diagnosis
of FMF and may have prognostic implications [12].
It was thus intriguing to study the prevalence of MEFV
gene polymorphisms as indictors of FMF in a group of Egyp-
tian children with HSP, and to study the possible association
of HSP with specific MEFV gene mutations, and to correlate,
as well, the MEFV gene mutations with the clinical and labo-
ratory characteristics of HSP.
2. Patients and methods
The present study is a case control study of 70 children; 40
HSP patients and 30 age and sex matched healthy children
as control. Patients with HSP were 17 males and 23 females,
with mean age at presentation of 7.5 ± 3.25 years, fulfilling
the criteria of the European League Against Rheumatism
(EULAR) and Pediatric Rheumatology European Society
(PRES) classification for HSP [13]. Children in the control
group were attending the outpatient clinic for regular follow-
up. The patients were diagnosed, treated and followed up at
the Specialized Children’s Hospital, Cairo University; in the
period October 2009 to December 2011. Patients were
subjected to detailed history taking, especially age at disease
onset, family history of HSP, history of recurrence of the dis-
ease and medications taken. Clinical presentation and diseasemanifestations were assessed. Established FMF cases were
excluded.
All patients were subjected to determination of complete
blood picture (CBC), erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), antistreptolysin O titer (ASOT),
blood urea nitrogen (BUN), serum creatinine, protein and
blood in urine, and for occult blood in stools.
For mutation analysis, 2 ml blood sample were withdrawn
from both patient and control groups in order to obtain geno-
mic DNA. Extraction of DNA molecule from peripheral blood
lymphocytes was done using standard procedures, then ampli-
fication of MEFV gene was done by polymerase chain reaction
(PCR). Reversed hybridization technique was used for identi-
fication of MEFV gene mutation. The Vienna Lab FMF Strip
Assay provides materials for the isolation of DNA from
human whole blood, the in vitro amplification of MEFV gene
sequences, and the subsequent detection of twelve mutations
by reverse-hybridization. The assay covers the following 12
MEFV mutations: E148Q, P369S, F479L, M680I (G/C),
M680I (G/A), I692del, M694V, M694I, K695R, V726A,
A744S, R761H [14]. Procedures followed were in accordance
with the ethical standards of the responsible committee and
the Helsinki Declaration. Informed consent was obtained from
children’s guardians.
Statistical analysis: The mean, standard deviation and the
percentage change were calculated. The relation between the
clinical and laboratory findings and mutations were analyzed
by Chi- square test, as part in Statistical Package for Social
Science (SPSS, windows version 21.0). Significance was
assigned to P values < 0.05.
3. Results
The age of patients at disease onset ranged from 2 to 15 years,
and the mean age of presentation of the patients was 7.5
± 3.25 years. The male: female ratio was 1:1.3. Positive family
history of HSP was found in 2 patients (5% of patients) and
recurrence of the disease occurred in 9 patients (22.5% of
patients).
Clinical manifestations among studied patients are
presented in Table 1. The mean ± SD ESR was 37.9
± 23.9 mm/h. Positive MEFV gene polymorphisms were
detected in 28 patients (70%): M680I in 20% (the commonest
gene mutation in this study), E148Q in 17.5%, V726A in 15%,
M694I in 7.5%, M694V in 5%, P369S in 2.5%, and multiple
polymorphisms (M680I +M694V + V726A) in 2.5%.
MEFV gene polymorphism was significantly lower in the con-
trol (36.7%) (p< 0.005). (Table 2). The Odds ratio of MEFV
mutation (as positive and negative) was 4.03 (4 times increased
risk).
The relation between the different MEFV gene polymor-
phisms and the clinical presentations, laboratory findings and
medications taken by the HSP patients are shown in Tables 3
and 4. Comparison of the demographic, clinical and laboratory
data between patients with HSP who had gene polymorphisms
and those who did not have gene polymorphisms is also pre-
sented (Tables 3 and 4). Arthritis, abdominal pain, GIT bleed-
ing, hypertension, anemia, proteinuria and positive occult
blood in stools, as well as recurrent HSP and positive family
history, were found to be more frequent presentations accom-
panying patients with positive gene polymorphisms.
Table 1 Clinical, laboratory and therapeutic data of Henoch–
Scho¨nlein purpura children.
Data n (%) HSP (n= 40)
Palpable purpura 40 (100)
Arthritis 31 (77.5)
Abdominal pain 31 (77.5)
GIT complication 9 (22.5)
Hypertension 1 (2.5)
Anemia 29 (72.5)
Leukocytosis 16 (40)
Thrombocytopenia 0 (0)
CRP 12 (30)
ASOT 5 (12.5)
Hematuria 8 (20)
Proteinuria 5 (12.5)
Increased BUN 0 (0)
Elevated creatinine 1 (2.5)
Stool for occult blood 10 (25)
MEFV gene mutation 28 (70)
NSAIDs 21 (52.5)
Corticosteroids 31 (77.5)
Immunosuppressive 2 (5)
HSP: Henoch–Scho¨nlein purpura, GIT: gastrointestinal tract,
CRP: C reactive protein, ASOT; antistreptolysin O titer, BUN:
blood urea nitrogen, MEFV: Mediterranean fever, NSAIDS: non-
steroidal anti-inflammatory drugs.
Subclinical Familial Mediterranean Fever and MEFV gene polymorphisms 3294. Discussion
Henoch–Schonlein purpura (HSP) is the most common type of
connective tissue diseases which increasingly occurs in children
in recent years and its pathogenesis remains unclear. Mecha-
nisms underlying the immunopathogenesis of the disease have
been postulated including Th1/Th2 imbalance and overactivity
of Th2 cells; increased level of IgA and consumed comple-
ments (C3 and C4); increased IgE mediated type-1 hypersensi-
tivity may cause an increase in capillary permeability and
proteinuria. Additionally, the reduced and impaired immune
function of NK cells were related to the renal and gastroin-
testinal injury [15]. It is the most common vasculitis in children
and the increased familial occurrence supports a genetic pre-
disposition. An association of HSP with HLA-DRB1*01 has
been confirmed and a protective effect against the development
of HSP appears to exist in Caucasians carrying the HLA-
DRB1*03 phenotype [16].Table 2 Percentage of MEFV gene mutations in Henoch–Scho¨nlei
MEFV gene mutation n (%) HSP pa
Positive 28)70)
E148Q 7/28 (25
P369S 1/28 (3.
V726A 6/28 (21
M680I 8/28 (28
M694I 3/28 (10
M694V and multiple (M680I +M694V+ V726A) 3/28 (10
HSP: Henoch–Scho¨nlein purpura, MEFV: Mediterranean fever.In the present study, the 40 HSP children had an age at dis-
ease onset ranging from 2 to 15 years and mean age at presen-
tation of 7.5 ± 3.25 years. The male: female ratio was 1:1.3.
HSP has been reported to occur most frequently at age of 4–
7 years [3,17] usually with a male preponderance [3,17,18],
but there are reports where a greater number of females has
been found to be affected [19]. Joint symptoms in HSP children
mostly occurred between 6 and 11 years of age [3].
The rash was present in all the current cases, typically pre-
senting with a palpable purpuric rash [20].
In the present study, arthritis was present in 77.5% of the
cases. Similarly, it has been reported that the incidence of joint
involvement in HSP patients could be as high as 78% [13].
Joint manifestations in HSP tend to be neglected due to their
mild nature. Moreover, atypical cases are liable to be misdiag-
nosed and mistreated. With the incidence increasing, investiga-
tion of every potential case and assessment of renal
involvement in these patients is important for the successful
management of HSP [3].
In this study, abdominal pain was present in 77.5% or the
cases and gastrointestinal complications in 22.5%. Abdominal
pain, vomiting and gastrointestinal bleeding are the most com-
mon symptoms in patients with HSP [17,18,21]. The reported
incidence of gastrointestinal symptoms could be as high as
34–75%. However, some reports have indicated gastrointesti-
nal bleeding as the most common symptom while in some
other reports pain was the most common symptom [3,17,18].
The initial clinical presentation with abdominal pain or
arthralgia may result in misdiagnosis of HSP [3].
FMF and HSP have clear clinical similarities and as the
frequency of association of the 2 diseases is indeed high, a
common etiologic factor has been suggested and an immune
complex mechanism might be the link between these 2 disease
entities [22]. HSP was reported to be the presenting feature of
FMF children. Pro-inflammatory cytokines, including
interleukin-1 (IL-1), IL-6, and tumor necrosis factor-a (TNF-
a), were reported to be involved in the pathogenesis [23].
The TNF-a-308GA genotype and A allele were reported to
contribute to the increased risk of nephritis in HSP children
[24]. Moreover, as HSP is characterized by small vessel vasculi-
tis, and FMF associated vasculitis is as frequent as some of the
rare manifestations of FMF, and may be even considered part
of the disease [5], HSP has been linked to MEFV gene muta-
tion [10,11]. Sometimes HSP associated with FMF differs from
typical isolated HSP. It was suggested that HSP should be con-
sidered to be associated with FMF as part of what we call
FMF rather than as co-existing additional separate clinical
entities [25].n purpura patients and in the control children.
tients (n= 40) Controls (n= 30) p
11(36.7) <0.005
) 4/11 (36.4) 0.75
6) 0 1
.4) 5/11 (45.5) 0.93
.6) 1/11 (9.1) 0.07
.7) 1/11 (9.1) 0.92
.7) 0 0.85
Table 3 Clinical presentations of HSP patients in relation to MEFV gene mutations.
Clinical presentation MEFV gene mutation in HSP patients (n= 40) p
+ve ve E148Q V726A P369S M680I M694I M694V Multiple
Age at Onset
(0–5 years) 8 3 2 2 0 3 0 1 0 1
(>5 years) 20 9 5 4 1 5 3 1 1
Sex Male 11 6 2 0 1 4 2 2 0 0.53
Female 17 6 5 6 0 4 1 0 1
Family history 2 0 1 1 0 0 0 0 0 1
Recurrence 7 2 2 2 0 0 2 0 1 0.7
Purpura 28 12 7 6 1 8 3 2 1 –
Arthritis/arthralgia 21 10 6 3 1 5 3 2 1 0.7
Abdominal pain 22 9 5 6 1 4 3 2 1 1
GIT complication 7 2 1 2 1 2 0 1 0 0.7
Hypertension 1 0 0 0 0 1 0 0 0 1
HSP: Henoch–Scho¨nlein purpura, MEFV: Mediterranean fever, GIT: gastrointestinal tract.
Table 4 Laboratory findings and medications used by HSP patients in relation to MEFV gene mutations.
Variable MEFV gene mutation in HSP patients (n= 40) p
+ve ve E148Q V726A P369S M680I M694I M694V Multiple
Laboratory
Anemia 20 9 4 4 1 6 3 1 1 1
Leucocytosis 9 7 3 2 1 2 0 0 1 0.12
Normal Pl count 28 12 7 6 1 8 3 2 1 -
CRP 7 5 2 2 0 2 0 1 0 0.45
ASOT 3 2 1 1 0 1 0 0 0 0.63
Normal BUN 28 12 7 6 1 8 3 2 1 -
Elevated creatinine 1 0 0 0 0 1 0 0 0 1
Proteinuria 4 1 1 1 0 2 0 0 0 1
Hematuria 4 4 1 1 0 1 0 0 1 0.21
Occult blood in stools 8 2 2 1 1 2 1 1 0 0.69
Medications
NSAIDs 16 5 4 4 0 3 2 2 1 0.37
Steroids 23 8 6 4 1 7 3 1 1 0.41
Immunosuppressives 1 1 0 0 0 0 0 0 1 0.52
Pl: Platelet, CRP: C reactive protein, ASOT: antistreptolysin O titer, BUN: blood urea nitrogen, NSAIDS: non-steroidal anti-inflammatory
drugs.
330 S. Salah et al.In the present study, MEFV gene polymorphisms were pos-
itive in 28 HSP patients (70%), while in the control group,
MEFV gene polymorphisms were positive in 11 children
(36.7%). The significantly higher incidence of MEFV gene
polymorphism in HSP patients compared to the control chil-
dren point to the possibility of increased susceptibility to
HSP affection with MEFV gene polymorphism. This work
confirms the increased frequency of a previous study [26]. Fur-
thermore, as Odds ratio of MEFV mutation (as positive and
negative) was found to be 4.03, this means that having a pos-
itive mutation increases the risk of having HSP four times than
normal.
Gershoni-Baruch et al. [10] reported that 26.9% of their
patients with HSP had positive MEFV gene mutations. Fur-
ther, Ozcakar et al. [11] stated that 34% of their pediatric
HSP patients were found to carry at least one of the screened
MEFV mutations. Moreover, 60% of their study group had
M694V mutation, which was detected in only 3% of the gen-eral population in Turkey. They added that these were impor-
tant findings because M694V mutation is known to be the
most common mutation in patients with FMF and is rarely
detected in the healthy controls.
In the present study, MEFV mutations in HSP patients
were more frequent than the two aforementioned studies. This
may be due to presence of mutations of low penetrance, like
E148Q, P396S and V726A, which represented about 50% of
the positive mutations. Also, in the control group, which
may give an idea about the general population carriers,
E148Q and V726A represented about 82% of positive muta-
tions. The most common mutations in the present study were
M680I (8/28; 28.6%) and E148Q (7/28; 25%). The positive
MEFV gene mutations in HSP patients seen herein, which
were 70%, could be divided into two groups; about 35% with
mutations of low penetrance and 35% of mutations of high
penetrance. So, in general, there is no difference between the
findings encountered in the present study and those of
Subclinical Familial Mediterranean Fever and MEFV gene polymorphisms 331Gershoni-Baruch et al. [10] and of Ozcakar et al. [11] in the
importance of MEFV gene mutations in the clinical course
and diagnosis of HSP. However, in a large study on Turkish
children with FMF, some had both FMF and HSP, and were
more likely to harbor either homozygote M694V or E148Q
mutations [27].
It has been suggested that MEFV mutations, especially
E148Q and M694V, might be associated with HSP and may
affect clinical presentation and laboratory findings [28]. This
study further throws light on the possible association with dif-
ferent clinical and laboratory findings. The present findings
that there were no significant relation existing between the
presence of MEFV gene polymorphisms in HSP and age of
patients or any of the clinical manifestations of the disease
agree with those of Gershoni-Baruch et al. [10] who found that
the clinical manifestations, such as fever, arthritis, gastroin-
testinal bleeding and hematuria, were equally distributed
among patients with or without mutated MEFV, regardless
the age of patients. On the other hand, they disagree with
the findings of Ozcakar et al. [11] that HSP patients with
MEFV polymorphisms are younger in age and had edema
and arthritis more frequently. As HSP is the most common
vasculitis seen in FMF children it may be important not to
overlook presence of MEFV mutations [29].
MEFV mutations in Turkish HSP children were present in
23.6%. and 2 mutated MEFV alleles were carried in 9.2%
which was higher than that observed in the general Turkish
population (1%) and similar to our results, they also reported
no significant differences in joint, gastrointestinal, renal
involvement, or subcutaneous edema, and also acute phase
reactants including leukocyte count, ESR, and serum CRP
concentration between those with and without polymor-
phisms. which seems that MEFV gene mutations may not have
any effect on the clinical presentation of HSP [30]. MEFV
mutations are more frequent in HSP than in the general pop-
ulation, and mutation carriers may have more severe clinical
findings with higher inflammatory response, suggesting a dys-
regulation of the inflammatory response because of defective
gene encoding the protein pyrine. Investigation of these muta-
tions may be beneficial to follow-up the susceptible patients
more closely leading to early diagnosis and treatment of
FMF [31].
These differences could be attributed to ethnicity difference
and, as well, to difference in MEFV genetic pattern. Although
there are no statistically significant differences in the distribu-
tion of clinical manifestations, laboratory findings or used
medications, in HSP patients with or without MEFV gene
polymorphisms, included in the present study, yet arthritis,
abdominal pain, GIT bleeding, hypertension, anemia, protein-
uria and positive occult blood in stools, as well as recurrent
HSP and positive family history, were found to be more fre-
quent presentations accompanying patients with positive poly-
morphisms. This would indicate that HSP patients with
positive MEFV gene polymorphisms could possibly have a
more aggressive disease course and would need more close fol-
low up. Further, it appears that no individual gene polymor-
phism increases the susceptibility to HSP.
In conclusion, Henoch–Schӧnlein purpura has a wide spec-
trum of presentations, and MEFV gene polymorphisms is rel-
evant to the development of HSP with a 4 time increased risk
and also to the disease manifestations in Egyptian children and
possibly also those of Mediterranean descent. Genetic testingfor MEFV gene is an advisable investigation in cases of
HSP. It could be of help in indefinite cases.
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